Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Quillivant XR Clear all
Completed Phase 4 Interventional Results available

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

NCT00776009
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 8, 2026, 2:29 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer

NCT01628029
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Sleep Disorder
Interventions
Counseling, Methylphenidate Hydrochloride, Phototherapy, Placebo Administration, Quality-of-Life Assessment, Sham Intervention, Therapeutic Melatonin
Other · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 8, 2026, 2:29 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD

NCT00141063
View directory record Official record
Conditions
ADHD
Interventions
Focalin XR
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Sep 8, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR

NCT00393042
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dexmethylphenidate, Mixed Amphetamine Salts, ER, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
9 Years to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois • Northbrook, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 8, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD

NCT02683265
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Aptensio XR, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 6 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Las Vegas, Nevada • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 8, 2026, 2:29 AM EDT
Terminated Phase 4 Interventional Results available

Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT04507204
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Adhansia XR, Concerta
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
12 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
35
States / cities
Dothan, Alabama • Beverly Hills, California • Cromwell, Connecticut + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 8, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD

NCT02470234
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Methylphenidate HCl ER Capsules, 10 mg, Methylphenidate HCl ER Capsules, 15 mg, Methylphenidate HCl ER Capsules, 20 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 5 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
South Miami, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 8, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Biomarkers of ADHD Treatment Response

NCT05650775
View directory record Official record
Conditions
ADHD
Interventions
Concerta, Adderall-XR
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
7 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 8, 2026, 2:29 AM EDT
Not listed Phase 4 Interventional

A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD

NCT02677519
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Aptensio XR
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 6 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Las Vegas, Nevada • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 8, 2026, 2:29 AM EDT
Recruiting Phase 4 Interventional

AWARE: Management of ADHD in Autism Spectrum Disorder

NCT05916339
View directory record Official record
Conditions
ADHD, Autism Spectrum Disorder
Interventions
Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
Drug
Lead sponsor
Daniel Coury
Other
Eligibility
4 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Irvine, California • Los Angeles, California • Portland, Maine + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 8, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study

NCT02255565
View directory record Official record
Conditions
ADHD, Autism
Interventions
Very Low Dose Quillivant XR, Low Dose Quillivant XR, Moderate Dose Quillivant XR
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
5 Years to 16 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 8, 2026, 2:29 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate

NCT00593138
View directory record Official record
Conditions
Drug Binding to DAT Receptors
Interventions
dex-methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Sep 8, 2026, 2:29 AM EDT
Not yet recruiting Phase 4 Interventional

Treating Young Children With Attention Deficit Hyperactivity Disorder

NCT07300956
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Guanfacine (GUA), Methylphenidate (MPH)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 5 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 8, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01835548
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
NT0102, Placebo
Drug
Lead sponsor
Neos Therapeutics, Inc
Industry
Eligibility
6 Years to 12 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 8, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body

NCT07314333
View directory record Official record
Conditions
ADHD
Interventions
Centanafadine, Methylphenidate, Lisdexamfetamine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 8, 2026, 2:29 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Stimulant Effects on Disruptive Behavior

NCT03420339
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Problem Behavior
Interventions
Stimulant
Drug
Lead sponsor
Matthew J O'Brien, PhD, BCBA-D
Other
Eligibility
48 Months to 12 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 8, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)

NCT00889915
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate transdermal system, Lisdexamfetamine dimesylate, Osmotic-release oral system methylphenidate (OROS MPH), Mixed amphetamine salts extended release
Drug
Lead sponsor
Duke University
Other
Eligibility
6 Years to 17 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced Sep 8, 2026, 2:29 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

NCT04419272
View directory record Official record
Conditions
Epilepsy
Interventions
Methylphenidate, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 8, 2026, 2:29 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Evaluating Treatment of ADHD in Children With Down Syndrome

NCT04219280
View directory record Official record
Conditions
Down Syndrome, ADHD
Interventions
Quillivant XR, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
4
States / cities
Sacramento, California • Boston, Massachusetts • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 8, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00564954
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dex-methylphenidate hydrochloride extended-release (Focalin XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
5
States / cities
Little Rock, Arkansas • Winter Park, Florida • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Sep 8, 2026, 2:29 AM EDT
Terminated Phase 2 Interventional

Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression

NCT00069927
View directory record Official record
Conditions
Depression, Neurotoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
Adderall-XR®, Concerta®
Drug
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
9
States / cities
Gainesville, Florida • Pensacola, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 8, 2026, 2:29 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children

NCT04987762
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Adhansia XR
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
4 Years to 12 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Colorado Springs, Colorado • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Sep 8, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

NCT00429273
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Guanfacine, Methylphenidate (MPH)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 14 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 8, 2026, 2:29 AM EDT
Not yet recruiting Phase 4 Interventional

EEG Biomarkers for ADHD Stimulant Treatment

NCT07650643
View directory record Official record
Conditions
ADHD
Interventions
methylphenidate HCl, Mixed amphetamine salts extended release
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
7 Years to 11 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 8, 2026, 2:29 AM EDT